Latest news with #FUJIFILM
Yahoo
4 days ago
- Business
- Yahoo
FUJIFILM Announces Expanded Capabilities for REVORIA PRESS™ Series with New Workflow, Specialty Toners, and Finishing Solutions
HANOVER PARK, Ill., August 11, 2025--(BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation Division, today announced three significant updates to its FUJIFILM REVORIA PRESS™ series designed to enhance productivity, expand creative possibilities, and streamline production for print service providers of all sizes. The new offerings include the availability of the Revoria XMF PressReady Lite workflow solution, new Silver & White specialty toners for select models, and the availability of the Plockmatic Booklet Maker on its EC2100 Series. "These new enhancements to our REVORIA PRESS series underscore our commitment to providing innovative and flexible solutions that help our customers thrive in a competitive market," said Yuji Oki, general manager, FUJIFILM North America Corporation, Business Innovation Division. "Whether it's a small shop needing an efficient workflow solution or a commercial printer looking to expand its specialty printing capabilities, these updates offer tangible benefits that drive business growth and customer satisfaction." Revoria XMF PressReady LiteA direct response to market need, the Revoria XMF PressReady Lite is a customized version of Fujifilm's original XMF PressReady workflow solution that is specifically designed to add value to smaller companies, especially those that only use one or two presses for production. The simplified, cost-effective workflow solution allows print providers to automate key tasks - including full PDF preflighting, file error detection and correction - in addition to creating automated workflows that intelligently group jobs by similar media or toner needs, minimizing changeovers and maximizing efficiency, ultimately saving time and reducing human error. As a software add-on, PressReady Lite can be installed on a Revoria Flow server configured for use with Fujifilm's Revoria Press SC285, EC2100, and PC1120 models. Silver & White Specialty TonersTo empower customers with the ability to produce more dynamic designs, Fujifilm is introducing new Silver & White specialty toners for its REVORIA PRESS EC2100S and SC285S models. Significantly broadening the creative potential and commercial appeal of digital print applications, these additions join the existing Pink, Clear, and Textured Clear options. The addition of Silver toner allows customers to produce stunning metallic effects that elevate branding for higher perceived value, making it ideal for high-end business cards, brochures, and promotional materials. White toner enables the production of vibrant, high-impact images on dark, transparent substrates, which is perfect for premium innovative marketing collateral. Together the addition of these two toners offers versatility without compromised quality, facilitates efficient workflows, allowing five-color printing in a single pass, and ultimately enables customers to differentiate in competitive markets. Plockmatic Booklet Maker Availability for EC2100 SeriesCompleting the comprehensive update, the Plockmatic Booklet Maker will now be available on the Revoria Press EC2100 series. This in-line finishing solution streamlines the production of high-quality booklets, brochures, and catalogs, reducing manual post-press processes and further increasing overall productivity. The Plockmatic Booklet Maker offers seamless integration, providing a complete end-to-end solution for a wide range of applications. Each of these solutions is now available in the North American market. For more information on Fujifilm's Business Innovation products, visit About Fujifilm FUJIFILM North America Corporation, a marketing subsidiary of FUJIFILM Holdings America Corporation, consists of six operating divisions. The Imaging Division provides consumer and commercial photographic products and services, including silver halide consumables; inkjet consumables; digital printing equipment, along with service and support; personalized photo products fulfillment; film; one-time-use cameras; and the popular INSTAX® line of instant cameras, smartphone printers, instant film, and accessories. The Electronic Imaging Division markets its GFX System and X Series lines of mirrorless digital cameras, lenses, and accessories to provide a variety of content creation solutions for both still and moving imagery. The Optical Devices Division provides optical lenses for the broadcast, cinematography, closed circuit television, videography, and industrial markets, and also markets binoculars and other optical imaging solutions. The Business Innovation Division offers a full lineup of digital print and toner technologies focused on enabling the digital transformation of businesses and print shops with its offerings of multifunction printers, digital inkjet presses, production toner printers, software, and more. The Industrial Products Division delivers new products derived from Fujifilm technologies including data storage tape products, including OEM and FUJIFILM Ultrium LTO cartridges, desalination solutions, microfilters and gas separation membranes. For more information, please visit go to to follow Fujifilm on X, or go to to Like Fujifilm on Facebook. FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here. FUJIFILM, REVORIA PRESS, and instax are trademarks of FUJIFILM Corporation and its affiliates. © 2025 FUJIFILM North America Corporation and its affiliates. All rights reserved. View source version on Contacts Media Contact:Daniel CarpenterFUJIFILM Holdings America Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Rising Cancer Cases and Adoption of Advanced Digital Biopsy Systems Drive Market Growth
The digital biopsy market, segmented by technique, indication, end-user, and geography, is anticipated to grow at a CAGR of 16.87% from 2025 to 2032. Increasing cancer rates globally and a shift toward non-invasive diagnostics are key drivers for market growth. North America is expected to lead due to technological advancements and high cancer incidence. Leading players include DermaSensor, SciBase, and FUJIFILM. Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Digital Biopsy - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to offering. The digital biopsy market is witnessing a significant upsurge, with projections indicating a compound annual growth rate (CAGR) of 16.87% from 2025 to 2032. This growth trajectory is fueled by the increasing global incidence of cancer and a marked shift towards non-invasive diagnostic procedures. A pivotal factor underpinning market expansion is the adoption of advanced digital biopsy systems that offer precise, real-time examination through innovative imaging technologies. Market Dynamics: According to GLOBOCAN (2023), new cancer cases reported globally numbered approximately 20 million in 2022, with expectations to rise to 32.6 million by 2045. This alarming trend underscores a critical need for efficient diagnostic technologies like digital biopsies. Skin cancer, one of the fastest-growing cancer types worldwide, contributes significantly to this demand. As the International Agency for Research on Cancer (IARC, 2022) reported, about 330,000 new melanoma cases were diagnosed globally in 2022. Digital biopsy tools, which offer a non-invasive approach to screening and early detection, are proving indispensable, particularly for melanoma and other skin cancers. Breast cancer continues to pose a global health challenge, as cited by the World Health Organization (2024), with 2.3 million diagnoses in 2022. Digital biopsy solutions play a crucial role here by differentiating between benign and malignant lesions, reducing unnecessary surgical interventions, and expediting diagnosis to improve patient outcomes. Additionally, the escalating prevalence of brain tumors points to a growing need for advanced diagnostics. Brain Tumour Research UK (2024) reported over 16,000 annual diagnoses in the UK. Digital biopsies facilitate tumor type and grade identification without invasive tissue removal, thus reducing patient risk and enabling prompt treatment interventions. Recent technological advancements are bolstering market momentum. Notably, in November 2023, the FDA approved BrainSpec's BrainSpec CoreT, a state-of-the-art non-invasive device for brain tumor detection, marking a significant leap in brain cancer diagnostics. Despite these advancements, challenges like technical limitations of existing devices and competition from alternative products persist, potentially restraining market growth. Market Segment Analysis: Radiofrequency imaging is anticipated to capture the largest market share by 2024, driven by its non-invasive nature and technological sophistication. These devices leverage AI and imaging technologies, providing real-time analysis while minimizing physical trauma and the risks associated with traditional biopsy methods. Technological innovation continues to drive growth. In January 2024, DermaSensor Inc. secured FDA clearance for a device aimed at detecting skin cancers, expanding non-invasive diagnostic solutions in primary care settings. Regional Insights: North America is poised to dominate the digital biopsy market, accounting for the largest share due to its robust healthcare infrastructure, favorable reimbursement policies, and high technological adoption. The U.S. alone saw 2,380,189 new cancer cases in 2022, with numbers expected to rise significantly by 2045. Technological advancements and new product approvals are propelling demand in North America, solidifying its leadership in the global market sphere. Key Market Players: Notable companies driving innovations in the digital biopsy market include DermaSensor, Inc., SciBase, VITA IMAGING, VPIX Medical Inc., BrainSpec, and others. These companies are at the forefront of developing cutting-edge, non-invasive diagnostic technologies. Recent Developments: Significant milestones include SciBase Holding AB's announcement in May 2025 that its Nevisense device had facilitated over 300,000 melanoma detection tests worldwide. The digital biopsy market report provides in-depth insights into market size, emerging trends, and future opportunities, offering a comprehensive guide for stakeholders poised to benefit from this expanding market. Key Topics Covered: 1. Digital Biopsy Market Report Introduction 1.1. Scope of the Study 1.2. Market Segmentation 1.3. Market Assumption 2. Digital Biopsy Market Executive Summary 2.1. Market at Glance 3. Competitive Landscape 4. Regulatory Analysis 4.1. The United States 4.2. Europe 4.3. Japan 4.4. China 5. Digital Biopsy Market Key Factors Analysis 5.1. Digital Biopsy Market Drivers 5.2. Digital Biopsy Market Restraints and Challenges 5.3. Digital Biopsy Market Opportunity 6. Digital Biopsy Market Porter's Five Forces Analysis 6.1. Bargaining Power of Suppliers 6.2. Bargaining Power of Consumers 6.3. Threat of New Entrants 6.4. Threat of Substitutes 6.5. Competitive Rivalry 7. Digital Biopsy Market Assessment 7.1. By Technique 7.2. By Indication 7.3. By End-User 7.4. By Geography 8. Digital Biopsy Market Company and Product Profiles 8.1. DermaSensor, Inc. 8.2. SciBase 8.3. VITA IMAGING, Inc. 8.4. MetaOptima Technology Inc. 8.5. VPIX Medical Inc. 8.6. Mauna Kea Technologies 8.7. Skin Analytics 8.8. Trafita Medical System 8.9. BRAINSPEC 8.10. Imaging Biometrics, LLC 8.11. Optovibronex, LLC 8.12. FUJIFILM Holdings Corporation 8.13. Canon Inc. 8.14. VivaScope GmbH 9. KOL Views 10. Project Approach For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25-07-2025
- Business
- Yahoo
Rising Infertility, Medical Advances, Government Supports and Societal Shifts Driving Growth
The Saudi Arabia IVF market is projected to grow from $306.59 million in 2024 to $522.39 million by 2033, driven by a 6.10% CAGR. Factors like rising infertility rates, delayed parenthood, technological advancements, and supportive government initiatives contribute to this growth. The market segments into procedure types, instruments, and end-users. Notable players include FUJIFILM Holdings and Merck & Co. Despite growth, challenges like high treatment costs and cultural sensitivities persist. Recent advancements, such as the discovery by King Faisal Specialist Hospital & Research Centre, underscore ongoing innovations in the field. Saudi Arabian IVF Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia IVF Market Outlook 2025-2033" report has been added to Arabia IVF Market is expected to reach US$ 522.39 million by 2033 from US$ 306.59 million in 2024, with a CAGR of 6.10% from 2025 to 2033 Increasing infertility rates, increased awareness, delayed parenthood, reproductive technology improvements, supportive government policies, increased medical tourism, higher disposable incomes, higher healthcare investments, improved healthcare infrastructure, and shifting cultural perceptions towards fertility treatments are some of the drivers of the Saudi Arabian IVF market. When it is difficult to conceive naturally, couples or individuals may have the medical procedure of in vitro fertilization (IVF) done to help conceive. To create an embryo, an egg and a sperm are joined outside the body in a laboratory. After fertilization, the resulting embryo is monitored before it is inserted into the woman's uterus in hopes of potential implantation and pregnancy. IVF is often employed to treat infertility caused by issues such as male infertility, blocked fallopian tubes, or unexplained infertility. To enhance the chances of a healthy pregnancy, the treatment may additionally include genetic testing, hormone therapy, egg harvesting, and freezing IVF market in Saudi Arabia is growing considerably owing to a variety of converging factors. Stress, lifestyle changes, and the rising age of first-time mothers are significant reasons for the high rates of infertility. Second, due to shifting social values and greater awareness of IVF options, there is greater societal acceptance of assisted reproduction. Treatment is becoming more appealing with greater success rates introduced by advances in technology such as genetic screening, freezing embryos, and intracytoplasmic sperm injection (ICSI). Market access is also supplemented by government initiatives, including subsidies and supportive healthcare legislation. In addition, Saudi Arabia's attempts to boost its medical tourism sector and enhance its health infrastructure cement its position as a regional hub for advanced reproductive Drivers for the Saudi Arabia IVF Market Delayed ParenthoodDelayed parenthood is one of the key drivers fueling the Saudi Arabian IVF market's growth. The first-time parents' average age keeps rising because more individuals and couples tend to prioritize their education, careers, and financial stability before having children. Delaying childbearing naturally reduces fertility, rendering IVF and other reproductive technologies more essential. This trend is being driven by changing social norms and greater acceptance of working women in Saudi Arabia. Lower reproduction rates are further linked to lifestyle and delayed marriages. Infertility treatments are increasingly being sought after with delayed motherhood gaining pace. IVF offers an effective solution, driving market growth as more people seek effective, scientifically validated solutions to age-related AdvancementsThe Saudi Arabian IVF industry is growing largely because of technological advancements. Intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and embryo vitrification are some of the advanced reproductive technologies that have increased IVF success rates significantly and made them more reliable and accessible. Couples who are facing problems with infertility are increasingly interested in these advances. To further expand its presence in the region, Burjeel Holdings PLC, a leading provider of super-specialty healthcare services, made plans in September 2024 to introduce IVF services in Saudi Arabia. Their Trust Fertility Clinic at Burjeel Medical City (BMC) will integrate with gynecology, fetal medicine, and pediatric subspecialties and IVF. BMC provides women with a seamless, superior reproductive experience from conception through birth in one, cutting-edge facility by offering full mother and baby care through specialized NICU and PICU SupportThe growth of the IVF market in Saudi Arabia is largely attributed to government support, which aligns with the Saudi Vision 2030 objectives of enhancing the quality and availability of healthcare. The government has entrusted the licensing and regulation of fertility clinics to the Ministry of Health, ensuring that the requirements of safety and effectiveness are fulfilled. To reduce economic burdens and provide better access to care, the government also offers funded help for IVF procedures to qualified individuals. The IVF sector has been further encouraged through massive investments in health infrastructure, including the development of advanced fertility centers. These programs combined create a friendly environment for individuals in need of fertility treatments, which stimulates market growth and positions Saudi Arabia as a front runner in the field for reproductive in the Saudi Arabia IVF Market Cultural and Religious SensitivitiesThe Saudi Arabian IVF market faces considerable obstacles due to cultural and religious sensitivity. In a culture steeped in Islamic customs, several forms of assisted reproduction, such surrogacy or third-party gamete donation, are typically forbidden by Islamic law. Compared to other nations, these limitations restrict the variety of IVF therapies that are available. Furthermore, frank conversations regarding infertility may be discouraged by conservative social norms, which could cause stigma and emotional hardship, particularly for women. Access to care is further diminished when people are reluctant to seek treatment out of fear of criticism or social pressure. Campaigns for culturally sensitive education and awareness are necessary to overcome these Treatment CostsIn the Saudi Arabian IVF industry, high treatment costs are a significant obstacle that prevents many couples from accessing fertility services. Because of the sophisticated equipment, skilled personnel, and numerous treatment cycles that are frequently necessary for success, IVF procedures can be costly. Although there is some government assistance, it is not very extensive, and many private insurance policies do not cover infertility treatments. Consequently, families with lower and intermediate incomes might find it difficult to pay for care, which could cause treatment to be postponed or stopped. These financial constraints highlight the need for more comprehensive insurance coverage and reasonably priced treatment options because they not only limit access but also heighten emotional stress. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, Sales Analysis FUJIFILM Holdings Corporation Hamilton Thorne Ltd. Vitrolife AB Thermo Fisher Scientific, Inc. Bayer AG Merck & Co., Inc. Boston IVF Fortis Healthcare Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $306.59 Million Forecasted Market Value (USD) by 2033 $522.39 Million Compound Annual Growth Rate 6.1% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia IVF Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Procedure Type6.2 By Instrument6.3 By Surgery6.4 By End Users7. Procedure Type7.1 Fresh non-donor7.2 Frozen non-donor7.3 Fresh Donor7.4 Frozen Donor8. Instrument8.1 Disposable Devices8.2 Culture Media8.3 Equipment9. Surgery9.1 Embryo Culture Media9.2 Cryopreservation Media9.3 Sperm Processing Media9.4 Ovum Processing Media10. End Users10.1 Fertility Clinics10.2 Hospitals & Other Setting11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian IVF Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Citizen
11-07-2025
- Health
- The Citizen
State of the art mammogram machine at Potch hospital
Potchefstroom Hospital in the Dr Kenneth Kaunda District has once again taken a step to be the facility of choice and the beacon of hope for quality patient care provision in the North West Province. This follows the installation of a brand-new mammogram machine to the tune of R 4 780 798. The FUJIFILM machine is a state-of-the-art device and the first of its kind in South Africa. It is now installed at the Potchefstroom Hospital CT Scan Unit. 'Mammogram is an exam used to detect breast cancer early and to identify abnormalities before symptoms appear. This can also assist in improving treatment outcomes and survival rates,' Chief Radiographer, Olga Sekwati, said. Breast cancer incidence is increasing, with 1 in 30 South African women at risk. Women need to schedule regular breast cancer screening tests to detect the disease at an early stage. Risk factors include family history, lifestyle, and genetic predisposition. 'Patients from Potchefstroom Hospital have been referred to Tshepong Hospital for mammogram examinations. The waiting period for bookings was very long, which caused delays in patients' management due to the long list at Tshepong Hospital,' Sekwati concluded. Risks for a long waiting period include the following: Some of the patients' conditions may be at an advanced stage even before proper diagnosis. The waiting period may result in metastasis. Patients may die before the doctor can see the extent of the cancer, or a proper diagnosis can be made. The new mammogram machine was installed at Potchefstroom Hospital in May and is performed by a qualified Mammographer, Tshegofatso Tsikwe. The department uses a booking system for referred patients. Patients should consult the Surgical OPD, where they can be seen by a doctor. If needed, the doctor will make an appointment with the X-Ray Department if there is a need. Working hours for mammogram services are from 7:30 to 16:00, only on Tuesdays and Thursdays. At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
National Post
26-06-2025
- Health
- National Post
FUJIFILM VisualSonics Launches the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform for Preclinical Ultrasound
Article content The world's first ultra-high to low frequency ultrasound system is designed to enhance research efforts across multiple applications, including oncology, cardiovascular, neurobiology and molecular biology Article content TORONTO — FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems, today announced the availability of the multi-modal Vevo F2 LAZR-X20 Photoacoustic Imaging Platform. The system features high-powered, intelligent laser technology for advanced tissue characterization with high anatomical accuracy for preclinical animal models. Article content 'For more than two decades, FUJIFILM VisualSonics has been delivering ultra-high frequency ultrasound and photoacoustic imaging solutions to the scientific research community,' said Greg Nesbitt, vice president, global high frequency, FUJIFILM VisualSonics Inc. 'As a leader in the space, we saw an opportunity to expand the scope of questions that can be answered using photoacoustics. The Vevo LAZR-X20 underscores our commitment to constantly innovating and bringing more applications and capabilities to a broader set of research domains.' The advanced laser technology in the Vevo F2 LAZR-X20 provides enhanced imaging depth and high-resolution in real time, allowing researchers to visualize and measure various tissue types and contrast agents. Leveraging a unique wavelength range of 660-1320 nm, the system unlocks advanced tissue characterization capabilities that were beyond reach with our previous-generation technologies. Tissue chromophores like lipids and collagen, which exhibit unique absorption profiles within this range, can be detected non-invasively. This enables researchers to visualize tumor microenvironments and opens the potential for quantifying therapeutic efficiency. This paves the way for possible deeper insights and more impactful discoveries. Article content 'This cutting-edge product represents a significant advancement in our portfolio, seamlessly integrating photoacoustics with ultrasound imaging into a single platform,' said Andrew Needles, director, product innovation, FUJIFILM VisualSonics Inc. 'The new system provides excellent image quality and an expanded spectral range, providing researchers with comprehensive data for their imaging studies. We believe this breakthrough technology will not only enhance current research capabilities but also has the potential to unlock new applications, particularly in the fields of oncology and neurobiology.' Article content Learn more about the multi-modal Vevo F2 LAZR-X20 here. About Fujifilm FUJIFILM VisualSonics, Inc., is a global leader in real time, in vivo, ultra-high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada and offices around the world, FUJIFILM VisualSonics is represented globally across an integrated sales network. FUJIFILM VisualSonics is recognized worldwide for providing cutting edge imaging technologies for the advancement of preclinical research, particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new preclinical product, FUJIFILM VisualSonics now broadens their range of imaging technologies across the preclinical market. FUJIFILM VisualSonics is a subsidiary of FUJIFILM Sonosite, Inc. and a part of FUJIFILM Holdings Corporation. For more information, please go to: Article content FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Marissa Confredo Article content Article content Article content
